The Cell and Gene Therapy Catapult (CGT Catapult) has announced a major investment in skills and capability training to help accelerate integration of cell and gene therapies into health services following their regulatory approval.
News
Mixed trial results for Lilly’s headache drug galcanezumab
Lilly has reported mixed trial data for its experimental therapy galcanezumab, showing efficacy in patients with episodic cluster headaches but failing in those with chronic cluster headache.
US clears Pfizer’s biosimilar or Epogen, Procrit
The US Food and Drug Administration has approved Pfizer’s Retacrit, a biosimilar of Amgen’s Epogen and Johnson & Johnson’s Procrit.
Novartis’ top lawyer resigns in wake of Trump scandal
Says $100,000-per-month contract with president’s lawyer was “legal but an error”
Lilly takes back cancer drug with AurKa buy
Eli Lilly has unveiled a deal to buy AurKa Pharma, bringing back in-house experimental fisrt-in-class cancer drug AK-01.
Elsevier/Bayer study findings could cut animal testing
A new analysis of safety reporting data by analytics group Elsevier and Bayer has found that some animal tests are far more predictive of human response than others.
Groups hails potential of organ on a chip tech for UK
The Medicines Discovery Catapult, the Centre for Drug Safety Sciences at the University of Liverpool and the National Centre for the Replacement Refinement & Reduction of Animals in Research are working together to “propel” the UK into the race to advance organ on a chip technology.
New mental health approach cuts hospital admissions 75 percent
A scheme being tested by the NHS that considers the mental health of patients with long-term conditions is being hailed a success, having reduced related hospital admissions by some 75 percent.
NHS Confederation launches petition on NHS funding plan
The NHS Confederation has launched a petition urging the government to commit to a funding plan for health and social care to 2035, to help address “crippling effects” of rising demand, underfunding and workforce shortages.
Coeliac UK, Innovate UK launch research competition
Coeliac UK and the UK’s Innovation Agency, Innovate UK are now taking applications from businesses and researchers wishing to access a fund of £750,000 to improve the detection and management of coeliac disease.
Emergex wins Innovate UK grant to advance universal flu vaccine
A UK biotech working on a pioneering a new approach to developing vaccines for infectious diseases has been awarded a grant of £979,318 by Innovate UK.
FDA approves Novartis’ Gilenya for paediatric use
US regulators have approved Novartis’ Gilenya to treat children and adolescents with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy indicated for this patient group.
Price cuts secure NHS place for MS drugs
NICE is now backing a trio of therapies to treat relapsing remitting forms of multiple sclerosis after price cuts enabled the cost regulator to endorse their routine use on the NHS.
Marketer of the Year – Enter now and stay one step ahead
2018 marks 25 years since the first PharmaTimes Marketer of the Year competition took place, and in that time the competition has helped thousands of marketers across the industry hone their skills, advance their careers and keep up to date with very latest business thinking.
The NEW PharmaTimes Sales Awards is open for entry
Not only is this this three-stage competition free to enter, it’s also the only pharmaceutical sales awards where representatives are evaluated by their healthcare professional clients, before pitting them head-to-head in a real life challenge against their peers.
